Hims’ pharmacy partner will reintroduce a compounded pill version of GLP-1 drug Wegovy that was pulled from the market last month, reported Shelby Livingston for Endpoints News.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Can Hims & Hers Overcome FDA’s GLP-1 Crackdown?
- Hims & Hers: Oversold Shares with Strong Platform but Regulated Headwinds Support a Balanced Hold Rating
- Hims & Hers Stock (HIMS) Surged 13.5% — Could More Gains Be Ahead?
- Hims, Qualcomm, IBM, First Solar, Oracle Trending With Analysts
- Mixed options sentiment in Hims and Hers Health with shares down 5.42%